GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics

Frontiers in Bioscience

Volumn 14, Issue 4, 2009, Pages 1558-1570

  Wada, Akihiko ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

AKT; Calcineurin; Cell protection; Chaperone; Diabetes mellitus; GSK 3 inhibitor; GSK 3 phosphorylation; Inflammation; Insulin receptor; IRS 1; IRS 2; Neurodegenerative diseases; Neurogenesis; Protein kinase C; Review

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; INSULIN RECEPTOR; LITHIUM DERIVATIVE; PROTEIN KINASE INHIBITOR; SERINE;

CHEMISTRY; CHROMAFFIN CELL; CYTOLOGY; DRUG ANTAGONISM; HUMAN; MENTAL DISEASE; METABOLISM; PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

CHROMAFFIN CELLS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM COMPOUNDS; MENTAL DISORDERS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, INSULIN; SERINE; SIGNAL TRANSDUCTION;

EID: 63849147445     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3324     Document Type: Article

References (112)

1. Wada A., Yokoo H., Yanagita T. & Kobayashi H.: Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J. Pharmacol. Sci. 99, 307-321 (2005). (Pubitemid 41813422)
2. Meijer L., Flajolet M. & Greengard P.: Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 25, 471-480 (2004). (Pubitemid 39149703)
3. Jope R.S., Yuskaitis C.J. & Beurel E.: Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32, 577-595 (2007). (Pubitemid 46481289)
4. Martinez A.: Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med. Res. Rev. 2008 Feb 12 [Epub ahead of print].
5. Takahashi-Yanaga F. & Sasaguri T.: The Wnt/β-catenin signaling pathway as a target in drug discovery. J. Pharmacol. Sci. 104, 293-302 (2007). (Pubitemid 47378416)
6. Hemmings B.A., Yellowlees D., Kernohan J.C. & Cohen P.: Purification of glycogen synthase kinase 3 from rabbit skeletal muscle. Copurification with the activating factor (FA) of the (Mg-ATP) dependent protein phosphatase. Eur. J. Biochem. 119, 443-451 (1981).
7. Jope R.S. & Johnson G.V.W.: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 29, 95-102 (2004). (Pubitemid 38186580)
8. Sugden P.H., Fuller S.J., Weiss S.C. & Clerk A.: Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Brit. J. Pharmacol. 153, S137- S153 (2008). (Pubitemid 351341012)
9. Clodfelder-Miller B., De Sarno P., Zmijewska A.A., Song L. & Jope R.S.: Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J. Biol. Chem. 280, 39723-39731 (2005). (Pubitemid 41779105)
10. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.-S., Jin O. & Woodgett J.R.: Requirement of glycogen synthase kinase- 3β in cell survival and NF-kB activation. Nature 406, 86-90 (2000). (Pubitemid 30460216)
11. Takada Y., Fang X., Jamaluddin M.S., Boyd D.D. & Aggarwal B.B.: Genetic deletion of glycogen synthase kinase-3β abrogates activation of IkBα kinase, JNK, Akt, and p44/42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J. Biol. Chem. 279, 39541-39554 (2004). (Pubitemid 39258221)
12. Yao H.-B., Shaw P.-C., Wong C.-C. & Wan D.C.-C.: Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J. Chem. Neuroanat. 23, 291-297 (2002). (Pubitemid 34606866)
13. Goode N., Hughes K., Woodgett J.R. & Parker P.J.: Differential regulation of glycogen synthase kinase-3β by protein kinase C isotypes. J. Biol. Chem. 267, 16878-16882 (1992).
14. Wang Q.M., Park I.K., Fiol C.J., Roach P.J. & DePaoli-Roach A.A.: Isoform differences in substrate recognition by glycogen synthase kinases 3 α and β in the phosphorylation of phosphatase inhibitor 2. Biochemistry 33, 143-147 (1994). (Pubitemid 24046506)
15. MacAulay K., Doble B.W., Patel S., Hansotia T., Sinclair E.M., Drucker D.J., Nagy A. & Woodgett J.R.: Glycogen synthase kinase 3α-specific regulation of murine hepatic glycogen metabolism. Cell Metab. 6, 329-337 (2007). (Pubitemid 47450185)
16. Hardt S.E. & Sadoshima J.: Negative regulators of cardiac hypertrophy. Cardiovasc. Res. 63, 500-509 (2004). (Pubitemid 38970194)
17. Zhai P., Gao S., Holle E., Yu X., Yatani A., Wagner T. & Sadoshima J.: Glycogen synthase kinase-3α reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J. Biol. Chem. 282, 33181-33191 (2007). (Pubitemid 350159328)
18. McManus E.J., Sakamoto K., Armit, L.J., Ronaldson, L., Shpiro N., Marquez R. & Alessi D.R.: Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 24, 1571- 1583 (2005). (Pubitemid 40646447)
19. Juhaszova M., Zorov D.B., Kim S.-H., Pepe S., Fu Q., Fishbein K.W., Ziman B.D., Wang S., Ytrehus K., Antos C.L., Olson E.N. & Sollott S.J.: Glycogen synthase kinase- 3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transient pore. J. Clin. Invest. 113, 1535-1549 (2004). (Pubitemid 39071677)
20. Liang M.-H. & Chuang D.-M.: Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J. Biol. Chem. 281, 30479-30484 (2006). (Pubitemid 44582104)
21. Liang M.-H. & Chuang D.-M.: Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J. Biol. Chem. 282, 3904-3917 (2007). (Pubitemid 47084481)
22. Koivisto L., Jiang G., Häkkinen L., Chan B. & Larjava H.: HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3α. Exp. Cell Res. 312, 2791-2805 (2006).
23. Aparicio I.M., Bragada M.J., Gil M.C., Garcia-Herreros M., Gonzalez-Fernandez L., Tapia J.A. & Garcia-Marin L.J.: Porcine sperm motility is regulated by serine phosphorylation of the glycogen synthase kinase-3α. Reproduction 134, 435-444 (2007). (Pubitemid 47386891)
24. Phiel C.J., Wilson C.A., Lee V.M.-Y & Klein P.S.: GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435-439 (2003). (Pubitemid 36626994)
25. Su Y., Ryder J., Li B., Wu X., Fox N., Solenberg P., Brune K., Paul S., Zhou Y., Liu F. & Ni B.: Lithium, a common drug for bipolar disorder treatment, regulates amyloid-β precursor protein processing. Biochemistry 43, 6899-6908 (2004). (Pubitemid 38720508)
26. Garrido J.J., Simón D., Varea O. & Wandosell F.: GSK3 alpha and GSK3 beta are necessary for axon formation. FEBS Lett. 581, 1579-1586 (2007). (Pubitemid 46528923)
27. Kim W.-Y., Zhou F.-Q., Zhou J., Yokota Y., Wang Y.-M., Yoshimura T., Kaibuchi K., Woodgett J.R., Anton E.S. & Snider W.D.: Essential roles for GSK-3s and GSK-3- primed substrates in neurotrophin-induced and hippocampal axon growth. Neuron 52, 981-996 (2006). (Pubitemid 44909402)
28. Doble B.W., Patel S., Wood G.A., Kockeritz L.K. & Woodgett J.R.: Functional redundancy of GSK-3α and GSK-3β in Wnt/β-catenin signaling shown in by using an allelic series of embryonic stem cell lines. Dev. Cell 12, 957-971 (2007). (Pubitemid 46805920)
29. Zhao Y., Altman B.J., Coloff J.L., Herman C.E., Jacobs S.R., Wieman H.L., Wofford J.A., Dimascio L.N., Ilkayeva O., Kelekar A., Reya T. & Rathmell J.C.: Glycogen synthase kinase 3α and 3β mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol. Cell. Biol. 27, 4328-4339 (2007). (Pubitemid 46906557)
30. Martin M., Rehani K., Jope R.S. & Michalek S.M.: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777-784 (2005). (Pubitemid 43090463)
31. Dugo L., Collin M., Allen D.A., Patel N.S., Bauer I., Mervaala E.M., Louhelainen M., Foster S.J., Yagoob M.M. & Thiemermann C.: GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit. Care Med. 33, 1903-1912 (2005). (Pubitemid 41306508)
32. Dugo L., Collin M., Allen D.A., Murch O., Foster S.J., Yagoob M.M. & Thiemermann C.: Insulin reduces the multiple organ injury and dysfunction caused by coadministrtation of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3β inhibition. Crit. Care Med. 34, 1489-1496 (2006).
33. Dugo L., Collin M. & Thiemermann C.: Glycogen synthase kinase 3β as a target for the therapy of shock and inflammation. Shock 27, 113-123 (2007). (Pubitemid 46105826)
34. Dugo L., Abdelrahman M., Murch O., Mazzon E., Cuzzocrea S. & Thiemermann C.: Glycogen synthase kinase-3β inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 25, 485-491 (2006).
35. Hu X., Paik P.K., Chen J., Yarilina A., Kockeritz L., Lu T.T., Woodgett J.R. & Ivashkiv L.B.: IFN-γ suppresses IL- 10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24, 563-574 (2006). (Pubitemid 43728157)
36. Whittle B.J.R., Varga C., Pósa A., Molnár A., Collin M. & Thiemermann C.: Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3β. Brit. J. Pharmacol. 147, 575-582 (2006). (Pubitemid 43355056)
37. Cuzzocrea S., Mazzon E., Di Paola R., Muià C., Crisafulli C., Dugo L., Collin M., Britti D., Caputi A.P. & Thiemermann C.: Glycogen synthase kinase-3β inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin. Immunol. 120, 57-67 (2006). (Pubitemid 43903390)
38. Cuzzocrea S., Genovese T., Mazzon E., Crisafulli C., Di Paola R., Muià C., Collin M., Esposito E., Bramanti P. & Thiemermann C.: Glycogen synthase kinase-3β inhibition reduces secondary damage in experimental spinal cord trauma. J. Pharmacol. Exp. Ther. 318, 79-89 (2006).
39. Zhu M., Tian D., Li J., Ma Y., Wang Y. & Wu R.: Glycogen synthase kinase 3β and β-catenin are involved in the injury and repair of bronchial epithelial cells induced by scratching. Exp. Mol. Pathol. 83, 30-38 (2007). (Pubitemid 46860294)
40. Bao Z., Lim S., Liao W., Lin Y., Thiemermann C., Leung B.P. & Wong W.S.F.: Glycogen synthase kinase-3β inhibition attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 176, 431-438 (2007). (Pubitemid 47358096)
41. Ougolkov A.V. & Billadeau D.D.: Targeting GSK-3: a promising approach for cancer therapy? Future Oncol. 2, 91-100 (2006).
42. Jope R.S.: Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24, 441-443 (2003). (Pubitemid 37088166)
43. Chalecka-Franaszek E. & Chuang D.-M.: Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. USA 96, 8745-8750 (1999). (Pubitemid 29354862)
44. Sasaki T., Han F., Shioda N., Moriguchi S., Kasahara J., Ishiguro K. & Fukunaga K.: Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res. 1108, 98-106 (2006). (Pubitemid 44278006)
45. Beaulieu J.-M., Sotnikova T.D., Yao W.-D., Kockeritz L., Woodgett J.R., Gainetdinov R.R. & Caron M.C.: Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. USA 101, 5099-5104 (2004). (Pubitemid 38469209)
46. O'Brien W.T., Harper A.D., Jové F., Woodgett J.R., Maretto S., Piccolo S. & Klein P.S.: Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24, 6791-6798 (2004). (Pubitemid 38993901)
47. Li X., Friedman A.B., Zhu W., Wang L., Boswell S., May R.S., Davis L.L. & Jope R.S.: Lithium regulates glycogen synthase kinase-3β in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol. Psychiatry 61, 216-222 (2007). (Pubitemid 46072775)
48. Nikoulina S.E., Ciaraldi T.P., Mudaliar S., Mohideen P., Carter L. & Henry R.R.: Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49, 263-271 (2000). (Pubitemid 30071005)
49. Ring D.B., Johnson K.W., Henriksen E.J., Nuss J.M., Goff D., Kinnick T.R., Ma S.T., Reeder J.W., Samuels I., Slabiak T., Wagman A.S., Hammond M.-E.W. & Harrison S.D.: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52, 588-595 (2003). (Pubitemid 36323563)
50. Rao R., Hao C.-M., Redha R., Wasserman D.H., McGuinness O.P. & Breyer M.D.; Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. Diabetologia 50, 452-460 (2007).
51. Robertson L.A., Kim A.J. & Werstuck G.H.: Mechanisms linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3. Can. J. Physiol. Pharmacol. 84, 39-48 (2006). (Pubitemid 44011949)
52. Kim A.J., Shi Y., Austin R.C. & Werstuck G.H.: Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. 118, 89-99 (2005). (Pubitemid 40277107)
53. Wada A., Yokoo H., Yanagita T. & Kobayashi H.: New twist on neuronal insulin receptor signaling in health, disease, and therapeutics. J. Pharmacol. Sci. 99, 128-143 (2005). (Pubitemid 41524451)
54. Engel T., Hernández F., Avila J. & Lucas J.J.: Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26, 5083-5090 (2006). (Pubitemid 44315289)
55. Castri P., Iacovelli L., De Blasi A., Giubilei F., Moretti A., Capone F.T., Nicoletti F. & Orzi F.: Reduced insulininduced phosphatidylinositol-3- kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. Eur. J. Neurosci. 26, 2469-2472 (2007). (Pubitemid 350050441)
56. Nakashima H., Ishihara T., Suguimoto P., Yokota O., Oshima E., Kugo A., Terada S., Hamamura T., Trojanowski J.O., Lee V.M.-Y. & Kuroda S.: Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 110, 547-556 (2005). (Pubitemid 41763984)
57. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J. & Luo J.: Glycogen synthase kinase 3β (GSK3β) mediates 6- hydroxydopamine-induced neuronal death. FASEB J. 18, 1162-1164 (2004). (Pubitemid 39561557)
58. Wang W., Yang Y., Ying C., Li W., Ruan H., Zhu X., You Y., Han Y., Chen R., Wang Y. & Li M.: Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52, 1678-1684 (2007). (Pubitemid 46843143)
59. Hu J.-H., Zhang H., Wagey R., Krieger C. & Pelech S.L.: Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J. Neurochem. 85, 432-442 (2003). (Pubitemid 36438338)
60. Koh S.-H., Kim Y., Kim H.Y., Hwang S., Lee C.H. & Kim S.H.: Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp. Neurol. 205, 336-346 (2007). (Pubitemid 46755762)
61. Carmichael J., Sugars K.L., Bao Y.P. & Rubinsztein D.C.: Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277, 33791-33798 (2002).
62. Nishihara M., Miura T., Miki T., Sakamoto J., Tanno M., Kobayashi H., Ikeda Y., Ohori K., Takahashi A. & Shimamoto K.: Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3β. Am. J. Physiol. Heart Circ. Physiol. 291, H748-H755 (2006). (Pubitemid 44175081)
63. Kelly S., Zhao H., Sun G.H., Cheng D., Qiao Y., Luo J., Martin K., Steinberg G.K., Harrison S.D. & Yenari M.A.: Glycogen synthase kinase 3β inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. Exp. Neurol. 188, 378-386 (2004). (Pubitemid 38891598)
64. Roh M.-S., Eom T.-Y., Zmijewska A.A., De Sarno P., Roth K.A. & Jope R.S.: Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol. Psychiatry 57, 278-286 (2005). (Pubitemid 40187372)
65. 2-induced apoptosis by glycogen synthase kinase-3 inhibitors. Neurosci. Lett. 400, 105-109 (2006).
66. Takadera T., Yoshikawa R. & Ohyashiki T.: Thapsigargin-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells. Neurosci. Lett. 408, 124-128 (2006). (Pubitemid 44498952)
67. Takadera T., Fujibayashi M., Kaniyu H., Sakota N. & Ohyashiki T.: Caspase-dependent apoptosis induced by thapsigargin was preventred by glycogen synthase kinase-3 inhibitors in cultured rat cortical neurons. Neurochem. Res. 32, 1336-1342 (2007). (Pubitemid 46988194)
68. Chin P.C., Majdzadeh N. & D'Mello S.R.: Inhibition of GSK3β is a common event in neuroprotection by different survival factors. Mol. Brain Res. 137, 193-201 (2005). (Pubitemid 40798902)
69. Sato N., Meijer L., Skaltsounis L., Greengard P. & Brivanlou A.H.: Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10, 55-63 (2004). (Pubitemid 38524699)
70. Trowbridge J.J., Xenocostas A., Moon R.T. & Bhatia M.: Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat. Med.12, 89-98 (2006). (Pubitemid 43050082)
71. Osakada F., Ooto S., Akagi T., Mandai M., Akaike A. & Takahashi M.: Wnt signaling promotes regeneration in the retina of adult mammals. J. Neurosci. 27, 4210-4219 (2007). (Pubitemid 46597155)
72. Emon T.-Y., Roth K.A. & Jope R.S.: Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. J. Biol. Chem. 282, 22856-22864 (2007). (Pubitemid 47267357)
73. Castelo-Branco G., Rawal N. & Arenas E.: GSK-3β inhibition/β-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J. Cell Sci. 117, 5731-5737 (2004). (Pubitemid 40123940)
74. Beaulieu J.-M.: Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int. J. Neuropsychopharmacol. 10, 3-6 (2007). (Pubitemid 46122747)
75. Li X., Zhu W., Roh M.-S., Friedman A.B., Rosborough K. & Jope R.S.: In vivo regulation of glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. Neuropsychopharmacology 29, 1426-1431 (2004). (Pubitemid 38982234)
76. Beaulieu J.-M., Zhang X., Rodriguiz R.M., Sotnikova T.D., Cools M.J., Wetsel W.C., Gainetdinov R.R. & Caron M.G.: Role of GSK3β in behavioral abnormalities induced by serotonin deficiency. Proc. Natl. Acad. Sci. USA 105, 1333-1338 (2008). (Pubitemid 351397053)
77. Li X., Rosborough K.M., Friedman A.B., Zhu W. & Roth K.A.: Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol. 10, 7-19 (2007). (Pubitemid 46122748)
78. Li X., Friedman A.B., Roh M.-S. & Jope R.S.: Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. J. Neurochem. 92, 701-704 (2005). (Pubitemid 40189472)
79. Sesti G., Federici M., Hribal M.L., Lauro D., Sbraccia P. & Lauro R.: Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 15, 2099-2111 (2001). (Pubitemid 32927927)
80. Sun H., Tu X., Prisco M., Wu A., Casiburi I. & Baserga R.: Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Mol. Endocrinol. 17, 472-486 (2003). (Pubitemid 36315640)
81. Chen J., Wu A., Sun H., Drakas R., Garofalo C., Cascio S., Surmacz E. & Baserga R.: Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and β-catenin. J. Biol. Chem. 280, 29912-29920 (2005). (Pubitemid 41177069)
82. Manning B.D.: Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167, 399-403 (2004). (Pubitemid 39489047)
83. Brazil D.P., Yang Z.-Z. & Hemmings B.A.: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29, 233-242 (2004). (Pubitemid 38591317)
84. Song G., Ouyang G. & Bao S.: The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9, 59-71 (2005).
85. Stambolic V. & Woodgett J.R.: Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol. 16, 461-466 (2006). (Pubitemid 44293397)
86. Yoeli-Lerner M. & Toker A.: Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5, 603-605 (2006).
87. Manning B.D. & Cantley L.C.: Akt/PKB signaling: navigating downstream. Cell 129, 1261-1274 (2007). (Pubitemid 46962095)
88. Russo S.J., Bolanos C.A., Theobald D.E., DeCarolis N.A., Renthal W., Kumar A., Winstanley C.A., Renthal N.E., Wiley M.D., Self D.W., Russell D.S., Neve R.L., Eisch A.J. & Nestler E.J.: IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat. Neurosci. 10, 93-99 (2007). (Pubitemid 46026532)
89. Martelli A.M., Faenza I., Billi A.M., Manzoli L., Evangelisti C., Falà F. & Cocco L.: Intranuclear 3'- phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell. Signal. 18, 1101-1107 (2006). (Pubitemid 43674029)
90. Hosoi T., Hyoda K., Okuma Y., Nomura Y. & Ozawa K.: Akt up- and down-regulation in response to endoplasmic reticulum stress. Brain Res. 1152, 27-31 (2007). (Pubitemid 46802507)
91. Parcellier A., Tintignac L.A., Zhuravleva E. & Hemmings B.A.: PKB and the mitochondria: AKTing on apoptosis. Cell. Signal. 20, 21-31 (2007).
92. Yamamoto R., Yanagita T., Kobayashi H., Yuhi T., Yokoo H. & Wada A.: Up-regulation of functional voltagedependent sodium channels by insulin in cultured bovine adrenal chromaffin cells. J. Neurochem. 67, 1401-1408 (1996). (Pubitemid 26314194)
93. Yamamoto R., Yanagita T., Kobayashi H., Yokoo H. & Wada A.: Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. J. Neurochem. 68, 1655-1662 (1997). (Pubitemid 27133075)
94. + channel expression. J. Pharmacol. Sci. 103(Suppl. I), 101P (2007).
95. Wada A.: Roles of voltage-dependent sodium channels in neuronal development, pain, and neurodegeneration. J. Pharmacol. Sci. 102, 253-268 (2006). (Pubitemid 44790687)
96. v1.7 sodium channels: multiple roles in adrenal chromaffin cells and peripheral nervous system. Acta Physiol. (Oxf) 192, 221-231 (2008). (Pubitemid 351160994)
97. Nemoto T., Yokoo H., Satoh S., Yanagita T., Sugano T., Yoshikawa N., Maruta T., Kobayashi H. & Wada A.: Constitutive activity of glycogen synthase kinase-3β: positive regulation of steady-state levels of insulin receptor substrates-1 and -2 in adrenal chromaffin cells. Brain Res. 1110, 1-12 (2006). (Pubitemid 44344594)
98. Yokoo H., Nemoto T., Yanagita T., Satoh S., Yoshikawa N., Maruta T. & Wada A.: Glycogen synthase kinase-3β: homologous regulation of cell surface insulin receptor level via controlling insulin receptor mRNA stability in adrenal chromaffin cells. J. Neurochem. 103, 1883-1896 (2007). (Pubitemid 350126638)
99. Nemoto T., Kanai T., Yanagita T., Satoh S., Maruta T., Yoshikawa N., Kobayashi H. & Wada A.: Regulation of Akt mRNA and protein levels by glycogen synthase kinase- 3β in adrenal chromaffin cells: effects of LiCl and SB216763. Eur. J. Pharmacol. 586, 82-89 (2008).
100. Kim B., van Golen C.M. & Feldman E.L.: Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3- kinase pathway in human neuroblastoma cells. Endocrinology 146, 5350-5357 (2005). (Pubitemid 41653048)
101. Saitoh T., Yanagita T., Shiraishi S., Yokoo H., Kobayashi H., Minami S., Onitsuka T. & Wada A.: Downregulation of cell surface insulin receptor and insulin receptor substrate-1 phosphorylation by inhibitor of 90-kDa heat-shock protein family: endoplasmic reticulum retention of monomeric insulin receptor precursor with calnexin in adrenal chromaffin cells. Mol. Pharmacol. 62, 847-855 (2002).
102. 2+-ATPase inhibitor in adrenal chromaffin cells. Brain Res. 898, 152-157 (2001). (Pubitemid 32274202)
103. Shiraishi S., Yokoo H., Kobayashi H., Yanagita T., Uezono Y., Minami S., Takasaki M. & Wada A.: Posttranslational reduction of cell surface expression of insulin receptors by cyclosporin A, FK506 and rapamycin in bovine adrenal chromaffin cells. Neurosci. Lett. 293, 211-215 (2000).
104. Yamamoto R., Kobayashi H., Yanagita T., Yokoo H., Kurose T., Shiraishi S., Minami S., Matsukura S. & Wada A.: Up-regulation of cell surface insulin receptor by protein kinase C-α in adrenal chromaffin cells: involvement of transcriptional and translational events. J. Neurochem. 75, 672-682 (2000). (Pubitemid 30485448)
105. Yokoo H., Saitoh T., Shiraishi S., Yanagita T., Sugano T., Minami S., Kobayashi H. & Wada A.: Distinct effects of ketone bodies on down-regulation of cell surface insulin receptor and insulin receptor substrate-1 phosphorylation in adrenal chromaffin cells. J. Pharmacol. Exp. Ther. 304, 994-1002 (2003). (Pubitemid 36254410)
106. Dajas-Bailador F. & Wonnacott S.: Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci. 25, 317-324 (2004). (Pubitemid 38692424)
107. Picciotto M.R. & Zoli M.: Nicotinic receptors in aging and dementia. J. Neurobiol. 53, 641-655 (2002). (Pubitemid 35375593)
108. 1-41 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. J. Biol. Chem. 272, 2038-2041 (1997). (Pubitemid 27058474)
109. Sugano T., Yanagita T., Yokoo H., Satoh S., Kobayashi H. & Wada A.: Enhancement of insulin-induced PI3K/Akt/GSK-3β and ERK signaling by neuronal nicotinic receptor/PKC-α/ERK pathway: up-regulation of IRS-1/-2 mRNA and protein in adrenal chromaffin cells. J. Neurochem. 98, 20-33 (2006). (Pubitemid 43882929)
110. Groth R.D., Dunbar R.L. & Mermelstein P.G.: Calcineurin regulation of neuronal plasticity. Biochem. Biophys. Res. Commun. 311, 1159-1171 (2003). (Pubitemid 37393439)
111. Oetjen E., Baun D., Beimesche S., Krause D., Cierny I., Blume R., Dickel C., Wehner S. & Knepel W.: Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol. Pharmacol. 63, 1289-1295 (2003). (Pubitemid 36627223)
112. Satoh S., Yanagita T., Maruta T., Nemoto T., Yoshikawa N., Kobayashi H., Tono T. & Wada A.: Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: attenuation of insulin-like growth factor-I-induced GSK-3β and ERK pathways in adrenal chromaffin cells. Neuropharmacology In press (2008).